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Within this document you find general information about the drug of interest and the indication it is 
intended to be used for. Further we have included full text publications and conference abstracts of 
phase III trials, assessing the safety and efficacy of the drugs of interest. 
At the very end of each chapter we have provided a table containing the prioritization criteria and a 
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Introduction 
As part of the project „Horizon Scanning in Oncology“ (further information can be found here: 
http://hta.lbg.ac.at/page/horizon-scanning-in-der-onkologie), 9 information sources are scanned 
frequently to identify emerging anticancer drugs. 
Every 3 months, these anticancer therapies are filtered (i.e. in most cases defined as availability of 
phase III results; for orphan drugs also phase II) to identify drugs at/around the same time as the 
accompanying drug licensing decisions of the EMA.  
An expert panel consisting of oncologists and pharmacists then applies 5 prioritisation criteria to 
elicit those anti-cancer therapies which might be associated with either a considerable impact on 
financial resources or a substantial health benefit.  
For the 33 prioritisation (October 2017), 9 drugs were filtered out of 401 identified and were sent to 
prioritisation. Of these, 5 drugs were ranked as ‘highly relevant’ by the expert panel, 4 as ‘relevant’ 
and none as ‘not relevant’. For ‘highly relevant’ drugs, further information including, for example, 
abstracts of phase III studies and licensing status is contained in this document. 
The summary judgements of the expert panel for all prioritised drugs are provided in the following 
table. 
 








Nivolumab (Opdivo®) in patients with metastatic DNA mismatch repair-deficient or 
microsatellite instability-high colorectal cancer (CheckMate 142) 
Highly 
relevant 
2. Adjuvant nivolumab (Opdivo®) versus ipilimumab in resected stage III or IV melanoma Relevant 
3. Adjuvant dabrafenib (Tafinlar®) plus trametinib in stage III BRAF-mutated melanoma Relevant 
4. 
Avelumab (Bavencio®) in patients with chemotherapy-refractory metastatic Merkel cell 
carcinoma Relevant 
5. Durvalumab (Imfinzi™) after chemoradiotherapy in stage III non–small-cell lung cancer  Highly 
relevant 
6. 





Idelalisib (Zydelig®) or placebo in combination with bendamustine and rituximab in 
patients with relapsed or refractory chronic lymphocytic leukaemia Relevant 
8. 





Abiraterone (Zytiga®) in combination with prednisone androgen-deprivation therapy in 




Horizon Scanning in Oncology    
 
Ergänzende Informationen zu den Arzneistoffen für Priorisierung XXXIII – HSS Onkologie Seite 4 von 14 
1 Colorectal cancer 
1.1 Nivolumab (Opdivo®) in patients with metastatic DNA mismatch 
repair-deficient or microsatellite instability-high colorectal 
cancer (CheckMate 142) 
 
Overview 
Drug Description humanized IgG4 anti-PD-1 monoclonal antibody 
Patient Indication nivolumab for metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer 
Incidence in 
Austria 
4,567 newly diagnosed per year (2014), 55.0/100,000/year (European 
Standard Population, 2013) 







07/2017: for the treatment of patients 12 years and older with mismatch repair 
deficient (dMMR) and microsatellite instability high (MSI-H) metastatic 
colorectal cancer that has progressed following treatment with a 






02/2016: for the treatment of non-small cell lung cancer (NSCLC) that has 
spread locally or to other parts of the body in patients who have previously 
been treated 
04/2016: as a monotherapy for advanced renal cell carcinoma in previously 
treated patients 
05/2016: for the treatment of advanced melanoma as a monotherapy or in 
combination with ipilimumab 
10/2016: for the treatment of adult patients with relapsed or refractory 
classical Hodgkin lymphoma after autologous stem cell transplant and 
treatment with brentuximab vedotin 
04/2017: for the treatment of squamous cell cancer of the head and neck 
(SCCHN) in adults progressing on or after platinum-based therapy for 
nivolumab as monotherapy 
06/2017: for the treatment of locally advanced unresectable or metastatic 
urothelial carcinoma in adults after failure of prior platinum-containing therapy 
for nivolumab 
FDA 
09/2015: BRAF V600 wild-type unresectable or metastatic melanoma, as a 
single agent  
09/2015: BRAF V600 mutation-positive unresectable or metastatic melanoma, 
as a single agent 
09/2015: unresectable or metastatic melanoma, in combination with 
ipilimumab 
10/2015: metastatic non-small cell lung cancer and progression on or after 
platinum based chemotherapy. Patients with EGFR or ALK genomic tumour 
aberrations should have disease progression on FDA-approved therapy for 
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these aberrations prior to receiving OPDIVO 
11/2015: advanced renal cell carcinoma who have received prior anti-
angiogenic therapy 
05/2016: for the treatment of patients with classical Hodgkin lymphoma that 
has relapsed or progressed after autologous hematopoietic stem cell 
transplantation and post-transplantation brentuximab vedotin  
11/2016: for the treatment of patients with recurrent or metastatic squamous 
cell carcinoma of the head and neck with disease progression on or after a 
platinum-based therapy 




1 treatment cycle: 3 mg/kg intravenously every 2 weeks (assuming an 
average body weight of 70 kg); ex-factory price of 40 mg =  
€ 572,-  € 6,006,- per treatment cycle 
Phase III results  
Lancet 2017 July, 18(9):1182-1191 (Overman et al.): “Nivolumab in patients with metastatic DNA 
mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-
label, multicentre, phase 2 study” 
Background 
Metastatic DNA mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) colorectal 
cancer has a poor prognosis after treatment with conventional chemotherapy and exhibits high levels 
of tumour neoantigens, tumour-infiltrating lymphocytes, and checkpoint regulators. All of these 
features are associated with the response to PD-1 blockade in other tumour types. Therefore, we 
aimed to study nivolumab, a PD-1 immune checkpoint inhibitor, in patients with dMMR/MSI-H 
metastatic colorectal cancer. 
 
Methods 
In this ongoing, multicentre, open-label, phase 2 trial, we enrolled adults (aged ≥18 years) with 
histologically confirmed recurrent or metastatic colorectal cancer locally assessed as dMMR/MSI-H 
from 31 sites (academic centres and hospitals) in eight countries (Australia, Belgium, Canada, France, 
Ireland, Italy, Spain, and the USA). Eligible patients had progressed on or after, or been intolerant of, 
at least one previous line of treatment, including a fluoropyrimidine and oxaliplatin or irinotecan. 
Patients were given 3 mg/kg nivolumab every 2 weeks until disease progression, death, unacceptable 
toxic effects, or withdrawal from study. The primary endpoint was investigator-assessed objective 
response as per Response Evaluation Criteria in Solid Tumors (version 1.1). All patients who received 
at least one dose of study drug were included in all analyses. This trial is registered with 
ClinicalTrials.gov, number NCT02060188. 
 
Findings 
Of the 74 patients who were enrolled between March 12, 2014, and March 16, 2016, 40 (54%) had 
received three or more previous treatments. At a median follow-up of 12·0 months (IQR 8.6–18.0), 23 
(31.1%, 95% CI 20.8–42.9) of 74 patients achieved an investigator-assessed objective response and 
51 (69%, 57–79) patients had disease control for 12 weeks or longer. Median duration of response 
was not yet reached; all responders were alive, and eight had responses lasting 12 months or longer 
(Kaplan-Meier 12-month estimate 86%, 95% CI 62–95). The most common grade 3 or 4 drug-related 
adverse events were increased concentrations of lipase (six [8%]) and amylase (two [3%]). 23 (31%) 
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Interpretation 
Nivolumab provided durable responses and disease control in pre-treated patients with dMMR/MSI-H 
metastatic colorectal cancer, and could be a new treatment option for these patients. 
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2 Lung cancer 
2.1 Durvalumab (Imfinzi™) after chemoradiotherapy in stage III 
non–small-cell lung cancer 
 
Overview 
Drug Description programmed death-ligand 1 (PD-L1) blocking antibody 
Patient Indication 
durvalumab as consolidation therapy in patients with stage III NSCLC who did 




4,716 newly diagnosed per year (2014), 56.9/100,000/year (European 
Standard Population, 2013) 













05/2017: for the treatment of patients with locally advanced or metastatic 
urothelial carcinoma who have disease progression during or following 
platinum-containing chemotherapy or who have disease progression within 12 
months of neoadjuvant or adjuvant treatment with platinum-containing 
chemotherapy 
Costs - 
Phase III results  
NEJM; published online 8 September 2017 (Antonia et al.): “Durvalumab after Chemoradiotherapy 
in Stage III Non–Small-Cell Lung Cancer” 
Background 
Most patients with locally advanced, unresectable, non–small-cell lung cancer (NSCLC) have disease 
progression despite definitive chemoradiotherapy (chemotherapy plus concurrent radiation therapy). 
This phase 3 study compared the anti–programmed death ligand 1 antibody durvalumab as 
consolidation therapy with placebo in patients with stage III NSCLC who did not have disease 
progression after two or more cycles of platinum-based chemoradiotherapy. 
 
Methods 
We randomly assigned patients, in a 2:1 ratio, to receive durvalumab (at a dose of 10 mg per kilogram 
of body weight intravenously) or placebo every 2 weeks for up to 12 months. The study drug was 
administered 1 to 42 days after the patients had received chemoradiotherapy. The coprimary end 
points were progression-free survival (as assessed by means of blinded independent central review) 
and overall survival (unplanned for the interim analysis). Secondary end points included 12-month and 
18-month progression-free survival rates, the objective response rate, the duration of response, the 
time to death or distant metastasis, and safety. 
 
Results 
Of 713 patients who underwent randomization, 709 received consolidation therapy (473 received 
durvalumab and 236 received placebo). The median progression-free survival from randomization was 
16.8 months (95% confidence interval [CI], 13.0 to 18.1) with durvalumab versus 5.6 months (95% CI, 
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4.6 to 7.8) with placebo (stratified hazard ratio for disease progression or death, 0.52; 95% CI, 0.42 to 
0.65; P<0.001); the 12-month progression-free survival rate was 55.9% versus 35.3%, and the 18-
month progression-free survival rate was 44.2% versus 27.0%. The response rate was higher with 
durvalumab than with placebo (28.4% vs. 16.0%; P<0.001), and the median duration of response was 
longer (72.8% vs. 46.8% of the patients had an ongoing response at 18 months). The median time to 
death or distant metastasis was longer with durvalumab than with placebo (23.2 months vs. 14.6 
months; P<0.001). Grade 3 or 4 adverse events occurred in 29.9% of the patients who received 
durvalumab and 26.1% of those who received placebo; the most common adverse event of grade 3 or 
4 was pneumonia (4.4% and 3.8%, respectively). A total of 15.4% of patients in the durvalumab group 
and 9.8% of those in the placebo group discontinued the study drug because of adverse events. 
 
Conclusions 
Progression-free survival was significantly longer with durvalumab than with placebo. The secondary 
end points also favored durvalumab, and safety was similar between the groups. (Funded by 
AstraZeneca; PACIFIC ClinicalTrials.gov number, NCT02125461.)  
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3 Lymphoma 
3.1 Brentuximab vedotin (Adcetris®) or physician's choice in CD30-
positive cutaneous T-cell lymphoma (ALCANZA) 
 
Overview 
Drug Description is an antibody-drug conjugate (ADC) directed to the protein CD30 
Patient Indication brentuximab vedotin in previously treated patients with CD30-positive 
cutaneous T-cell lymphomas 
Incidence in 
Austria 
1,272 newly diagnosed per year (2014), 15.3/100,000/year (European 
Standard Population, 2013) 






FDA The FDA granted Priority Review for Brentuximab vedotin in CD30-positive 






10/2012: Adcetris is indicated for the treatment of adult patients with relapsed 
or refractory CD30+ Hodgkin lymphoma (HL): 
 
• following autologous stem-cell transplant (ASCT) or; 
• following at least two prior therapies when ASCT or multi-agent 
chemotherapy is not a treatment option. 
 
Adcetris is indicated for the treatment of adult patients with relapsed or 
refractory systemic anaplastic large-cell lymphoma (sALCL). 
 
06/2016: Adcetris is indicated for the treatment of adult patients with CD30+ 
HL at increased risk of relapse or progression following ASCT. 
FDA 
08/2011: for the treatment of patients with Hodgkin lymphoma after failure of 
autologous stem cell transplant (ASCT) or after failure of at least two prior 
multi-agent chemotherapy regimens in patients who are not ASCT 
candidates. 
 
08/2011: for the treatment of patients with systemic anaplastic large cell 




1 treatment cycle  1.8 mg/kg once every 3 weeks (assuming an average 
body weight of 70 kg); ex-factory price of 50 mg =  
€ 3,333.00,-  € 8,399.16,- per treatment cycle 
Phase III results  
Lancet 2017 August, 390(10094):555-566 (Prince et al.): “Brentuximab vedotin or physician's choice 
in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, 
phase 3, multicentre trial” 
Background 
Cutaneous T-cell lymphomas are rare, generally incurable, and associated with reduced quality of life. 
Present systemic therapies rarely provide reliable and durable responses. We aimed to assess 
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efficacy and safety of brentuximab vedotin versus conventional therapy for previously treated patients 
with CD30-positive cutaneous T-cell lymphomas. 
 
Methods 
In this international, open-label, randomised, phase 3, multicentre trial, we enrolled adult patients with 
CD30-positive mycosis fungoides or primary cutaneous anaplastic large-cell lymphoma who had been 
previously treated. Patients were enrolled across 52 centres in 13 countries. Patients were randomly 
assigned (1:1) centrally by an interactive voice and web response system to receive intravenous 
brentuximab vedotin 1.8 mg/kg once every 3 weeks, for up to 16.3-week cycles, or physician's choice 
(oral methotrexate 5–50 mg once per week or oral bexarotene 300 mg/m2 once per day) for up to 48 
weeks. The primary endpoint was the proportion of patients in the intention-to-treat population 
achieving an objective global response lasting at least 4 months per independent review facility. 
Safety analyses were done in all patients who received at least one dose of study drug. This trial was 
registered with ClinicalTrials.gov, number NCT01578499. 
 
Findings 
Between Aug 13, 2012, and July 31, 2015, 131 patients were enrolled and randomly assigned to a 
group (66 to brentuximab vedotin and 65 to physician's choice), with 128 analysed in the intention-to-
treat population (64 in each group). At a median follow-up of 22.9 months (95% CI 18.4–26.1), the 
proportion of patients achieving an objective global response lasting at least 4 months was 56·3% (36 
of 64 patients) with brentuximab vedotin versus 12·5% (eight of 64) with physician's choice, resulting 
in a between-group difference of 43·8% (95% CI 29.1–58.4; p<0·0001). Grade 3–4 adverse events 
were reported in 27 (41%) of 66 patients in the brentuximab vedotin group and 29 (47%) of 62 patients 
in the physician's choice group. Peripheral neuropathy was seen in 44 (67%) of 66 patients in the 
brentuximab vedotin group (n=21 grade 2, n=6 grade 3) and four (6%) of 62 patients in the physician's 
choice group. One of the four on-treatment deaths was deemed by the investigator to be treatment-




Significant improvement in objective response lasting at least 4 months was seen with brentuximab 
vedotin versus physician's choice of methotrexate or bexarotene. 
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4 Leukaemia 
4.1 Midostaurin (Rydapt®) plus chemotherapy for acute myeloid 
leukemia with a FLT3 mutation 
 
Overview 
Drug Description a small molecule that inhibits multiple receptor tyrosine kinases 
Patient Indication midostaurin in combination to standard chemotherapy in patients with acute 
myeloid leukemia and a FLT3 mutation 
Incidence in 
Austria 
936 newly diagnosed per year (2014), 11.3/100,000/year (European Standard 
Population, 2013) 






On 20 July 2017, the Committee for Medicinal Products for Human Use 
(CHMP) adopted a positive opinion, recommending the granting of a 
marketing authorisation for the medicinal product Rydapt, intended for the 
treatment of adult patients with newly diagnosed acute myeloid leukaemia 
(AML) who are FLT3 mutation-positive and for the treatment of adult patients 
with aggressive systemic mastocytosis (ASM), systemic mastocytosis with 
associated haematological neoplasm (SM AHN), or mast cell leukaemia 
(MCL). Rydapt was designated as an orphan medicinal product on 29 July 
2004 
FDA 
04/2017: for the treatment of adult patients with newly diagnosed acute 
myeloid leukemia (AML) who are FLT3 mutation-positive (FLT3+), as 
detected by an FDA-approved test, in combination with standard cytarabine 






08/2010, orphan designation was granted by the European Commission to 
Novartis Europharm Limited, United Kingdom, for midostaurin for the 
treatment of mastocytosis. 
FDA 
04/2017: midostaurin for the treatment of adults with aggressive systemic 
mastocytosis (SM), SM with associated hematological neoplasm, or mast cell 
leukemia. 
Costs - 
Phase III results  
Lancet published online June 2017, (Stone et al.) “Midostaurin plus Chemotherapy for Acute 
Myeloid Leukemia with a FLT3 Mutation” 
Background 
Patients with acute myeloid leukemia (AML) and a FLT3 mutation have poor outcomes. We conducted 
a phase 3 trial to determine whether the addition of midostaurin — an oral multitargeted kinase 
inhibitor that is active in patients with a FLT3 mutation — to standard chemotherapy would prolong 
overall survival in this population. 
 
Methods 
We screened 3277 patients, 18 to 59 years of age, who had newly diagnosed AML for FLT3 
mutations. Patients were randomly assigned to receive standard chemotherapy (induction therapy with 
daunorubicin and cytarabine and consolidation therapy with high-dose cytarabine) plus either 
midostaurin or placebo; those who were in remission after consolidation therapy entered a 
maintenance phase in which they received either midostaurin or placebo. Randomization was stratified 
according to subtype of FLT3 mutation: point mutation in the tyrosine kinase domain (TKD) or internal 
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tandem duplication (ITD) mutation with either a high ratio (>0.7) or a low ratio (0.05 to 0.7) of mutant to 
wild-type alleles (ITD [high] and ITD [low], respectively). Allogeneic transplantation was allowed. The 
primary end point was overall survival. 
 
Results 
A total of 717 patients underwent randomization; 360 were assigned to the midostaurin group, and 
357 to the placebo group. The FLT3 subtype was ITD (high) in 214 patients, ITD (low) in 341 patients, 
and TKD in 162 patients. The treatment groups were well balanced with respect to age, race, FLT3 
subtype, cytogenetic risk, and blood counts but not with respect to sex (51.7% in the midostaurin 
group vs. 59.4% in the placebo group were women, P = 0.04). Overall survival was significantly longer 
in the midostaurin group than in the placebo group (hazard ratio for death, 0.78; one-sided P = 0.009), 
as was event-free survival (hazard ratio for event or death, 0.78; one-sided P = 0.002). In both the 
primary analysis and an analysis in which data for patients who underwent transplantation were 
censored, the benefit of midostaurin was consistent across all FLT3 subtypes. The rate of severe 
adverse events was similar in the two groups. 
 
Conclusions 
The addition of the multitargeted kinase inhibitor midostaurin to standard chemotherapy significantly 
prolonged overall and event-free survival among patients with AML and a FLT3 mutation. (Funded by 
the National Cancer Institute and Novartis; ClinicalTrials.gov number, NCT00651261.) 
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5 Prostate caner 
5.1 Abiraterone (Zytiga®) in combination with prednisone 
androgen-deprivation therapy in metastatic, castration-
sensitive prostate cancer 
 
Overview 
Drug Description an androgen biosynthesis inhibitor, that inhibits 17 α-hydroxylase/C17,20-lyase (CYP17) 
Patient Indication Abiraterone in combination with prednisone androgen-deprivation therapy in 
metastatic, castration-sensitive prostate cancer 
Incidence in 
Austria 
4,499 newly diagnosed per year (2014), 124.0/100,000/year (European 
Standard Population, 2013) 












09/2011: in combination with prednisone or prednisolone for the treatment of 
metastatic castration resistant prostate cancer in adult men whose disease 
has progressed on or after a docetaxel based chemotherapy regimen. 
 
12/2012: in combination with prednisone or prednisolone for the treatment of 
metastatic castration resistant prostate cancer in adult men who are 
asymptomatic or mildly symptomatic after failure of androgen deprivation 
therapy in whom chemotherapy is not yet clinically indicated. 
FDA 04/2011: in combination with prednisone for the treatment of patients with 
metastatic castration-resistant prostate cancer. 
Costs 
Abiraterone:  
1,000 mg orally (given once daily as four 250-mg tablets); ex-factory price of 
28,000 mg = € 2,895.35,-  € 2,171.51 for 21 days of treatment  
Phase III results 
NEJM published online June 2017 (Fizazi et al.) “Abiraterone plus Prednisone in Metastatic, 
Castration-Sensitive Prostate Cancer” 
Background 
Abiraterone acetate, a drug that blocks endogenous androgen synthesis, plus prednisone is indicated 
for metastatic castration-resistant prostate cancer. We evaluated the clinical benefit of abiraterone 
acetate plus prednisone with androgen-deprivation therapy in patients with newly diagnosed, 
metastatic, castration-sensitive prostate cancer. 
Methods 
In this double-blind, placebo-controlled, phase 3 trial, we randomly assigned 1199 patients to receive 
either androgen-deprivation therapy plus abiraterone acetate (1000 mg daily, given once daily as four 
250-mg tablets) plus prednisone (5 mg daily) (the abiraterone group) or androgen-deprivation therapy 
plus dual placebos (the placebo group). The two primary end points were overall survival and 
radiographic progression-free survival. 
Results 
After a median follow-up of 30.4 months at a planned interim analysis (after 406 patients had died), the 
median overall survival was significantly longer in the abiraterone group than in the placebo group (not 
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reached vs. 34.7 months) (hazard ratio for death, 0.62; 95% confidence interval [CI], 0.51 to 0.76; 
P<0.001). The median length of radiographic progression-free survival was 33.0 months in the 
abiraterone group and 14.8 months in the placebo group (hazard ratio for disease progression or 
death, 0.47; 95% CI, 0.39 to 0.55; P<0.001). Significantly better outcomes in all secondary end points 
were observed in the abiraterone group, including the time until pain progression, next subsequent 
therapy for prostate cancer, initiation of chemotherapy, and prostatespecific antigen progression 
(P<0.001 for all comparisons), along with next symptomatic skeletal events (P = 0.009). These 
findings led to the unanimous recommendation by the independent data and safety monitoring 
committee that the trial be unblended and crossover be allowed for patients in the placebo group to 




The addition of abiraterone acetate and prednisone to androgen-deprivation therapy significantly 
increased overall survival and radiographic progression-free survival in men with newly diagnosed, 
metastatic, castration-sensitive prostate cancer. (Funded by Janssen Research and Development; 
LATITUDE ClinicalTrials.gov number, NCT01715285.) 
NEJM published online June 2017 (James et al.) “Abiraterone for Prostate Cancer Not Previously 
Treated with Hormone Therapy” 
Background 
Abiraterone acetate plus prednisolone improves survival in men with relapsed prostate cancer. We 
assessed the effect of this combination in men starting long-term androgen-deprivation therapy (ADT), 
using a multigroup, multistage trial design. 
Methods 
We randomly assigned patients in a 1:1 ratio to receive ADT alone or ADT plus abiraterone acetate 
(1000 mg daily) and prednisolone (5 mg daily) (combination therapy). Local radiotherapy was 
mandated for patients with node-negative, nonmetastatic disease and encouraged for those with 
positive nodes. For patients with nonmetastatic disease with no radiotherapy planned and for patients 
with metastatic disease, treatment continued until radiologic, clinical, or prostate-specific antigen 
(PSA) progression; otherwise, treatment was to continue for 2 years or until any type of progression, 
whichever came first. The primary outcome measure was overall survival. The intermediate primary 
outcome was failure-free survival (treatment failure was defined as radiologic, clinical, or PSA 
progression or death from prostate cancer). 
 
Results 
A total of 1917 patients underwent randomization from November 2011 through January 2014. The 
median age was 67 years, and the median PSA level was 53 ng per milliliter. A total of 52% of the 
patients had metastatic disease, 20% had node-positive or node-indeterminate nonmetastatic disease, 
and 28% had node-negative, nonmetastatic disease; 95% had newly diagnosed disease. The median 
follow-up was 40 months. There were 184 deaths in the combination group as compared with 262 in 
the ADT-alone group (hazard ratio, 0.63; 95% confidence interval [CI], 0.52 to 0.76; P<0.001); the 
hazard ratio was 0.75 in patients with nonmetastatic disease and 0.61 in those with metastatic 
disease. There were 248 treatment-failure events in the combination group as compared with 535 in 
the ADT-alone group (hazard ratio, 0.29; 95% CI, 0.25 to 0.34; P<0.001); the hazard ratio was 0.21 in 
patients with nonmetastatic disease and 0.31 in those with metastatic disease. Grade 3 to 5 adverse 
events occurred in 47% of the patients in the combination group (with nine grade 5 events) and in 33% 
of the patients in the ADT-alone group (with three grade 5 events). 
 
Conclusion 
Among men with locally advanced or metastatic prostate cancer, ADT plus abiraterone and 
prednisolone was associated with significantly higher rates of overall and failure-free survival than 
ADT alone. (Funded by Cancer Research U.K. and others; STAMPEDE ClinicalTrials.gov number, 
NCT00268476, and Current Controlled Trials number, ISRCTN78818544.) 
